title: More on risk/benefit ratio of anti-IL-2 receptor monoclonal antibodies.
authors.affiliation: Departments of Nephrology and Clinical Immunology, Transplantation, ITUN, Nantes University Hospital, Nantes, France. jean-paul.soulillou@univ-nantes.fr
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Soulillou
authors.forename: Diego
authors.initials: D
authors.lastname: Cantarovich
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006084:Graft Rejection / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D053645:Interleukin-2 Receptor alpha Subunit / Q000276:immunology; D016030:Kidney Transplantation / Q000276:immunology*; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D012189:Retrospective Studies; D018570:Risk Assessment; D019172:Transplantation Conditioning / Q000379:methods
chemical_list: D000911:Antibodies, Monoclonal; D053645:Interleukin-2 Receptor alpha Subunit; D015375:Receptors, Interleukin-2